Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
NEW YORK (Reuters Health) – As the number of prescribed antithrombotic drugs after a first myocardial infarction increases, so does the risk of hospitalization for bleeding, according to…
NEW YORK (Reuters Health) – In children with attention deficit hyperactivity disorder (ADHD), adding divalproex to stimulant therapy can improve refractory aggression, a small study suggests. “Stimulant medications…
NEW YORK (Reuters Health) – Breast cancer recurrence rates are lower with aromatase inhibitors than with tamoxifen, according to meta-analyses published online by the Journal of Clinical Oncology.…
NEW YORK (Reuters Health) – Abatacept, an agent that modifies the costimulatory signal required for T-cell activation, does not increase malignancy rates in patients with rheumatoid arthritis (RA),…
NEW YORK (Reuters Health) – Methadone is a safe, effective first- or second-line treatment of cancer pain, even in outpatients, a retrospective study suggests. Concerns over its long…
NEW YORK (Reuters Health) – For men with hot flushes from androgen suppression for prostate cancer, medroxyprogesterone appears to be the best option for relief, according to a…
NEW YORK (Reuters Health) – New research suggests that high-dose vitamin D can be safely given to breast cancer patients with bone metastases, but it will not affect…
NEW YORK (Reuters Health) – Recombinant human erythropoietin (EPO) provides no benefit after acute ischemic stroke, and may even be dangerous, particularly in patients receiving systemic thrombolysis. These…
NEW YORK (Reuters Health) – New research shows that antidiabetes agents are not equal when it comes to cardiovascular risks and mortality. According to a report in the…
NEW YORK (Reuters Health) – In treating patients with metastatic melanoma, thalidomide plus temozolomide is no better than temozolomide or dacarbazine alone, according to a report in the…
